CD30


Also found in: Wikipedia.

CD30

a type I transmembrane protein present on activated T and B cells that may play a role in cell activation and/or differentiation; expressed in Hodgkin disease, some T-cell lymphomas, and anaplastic large cell lymphomas.
References in periodicals archive ?
CD30 assessment is recommended because of the potential utility of the anti-CD30 antibody-drug conjugate brentuximab vedotin.
Brentuximab binds and is internalized by cells that express the CD30 antigen; subsequently, MMAE causes cell cycle arrest and apoptosis [5].
Based on immunohistologic characteristics of strong CD30 positivity, coexpression with CD3/CD4 antigens, light EMA positivity, CD20 and Alk-1 negativity, and 15% Ki-67 proliferation rate with no apparent cells of the Reed-Sternberg morphology, possibility of a peripheral T-cell lymphoma was considered.
Immunostaining revealed LCA, CD30 and CD3 Positive while ALK was negative.
Brentuximab vedotin is a type of monoclonal antibody that targets a protein called CD30 that is found on Hodgkin's lymphoma cells and anaplastic large cell lymphoma (ALCL) cells.
All the cases were positive for CD30 while 23 (92%) cases for CD3, 22 (88 %) cases for ALK and 19 (76%) cases positive for EMA.
Expression of epithelial membrane antigen and CD30 are frequently seen.
To determinate, relationship between variations of CD30 marker expressed in cancerous cells and clonality rates, the Pearson's chi-square ([chi square] test) and Fisher's exact tests were performed.
Expression of CD30 (an activation marker for B or T cells) in more than 75% of neoplastic cells characterizes this group of lympho-proliferative disorders.
Immunohistokimyasal incelemede lenfosit lerde CD20 ve CD3 antijenlerinin pozitif oldugu ve seyrek olarak CD30 ile pozitif reaktivite veren aktive lenfositler goruldu.
The CD30 molecule, a member of the TNF superfamily of membrane cytokine receptors, is expressed by activated CD4+T cells predominantly producing Th2 type cytokines in vitro (8).